Serina Therapeutics Inc
SER2.370USD
-0.090-3.64%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
24.99MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Serina Therapeutics Inc Unternehmen
Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
Serina Therapeutics Inc Informationen
BörsenkürzelSER
Name des UnternehmensSerina Therapeutics Inc
IPO-datumNov 29, 2018
CEOLedger (Steven)
Anzahl der mitarbeiter12
WertpapierartOrdinary Share
GeschäftsjahresendeNov 29
Addresse601 Genome Way,
StadtHUNTSVILLE
BörseNASDAQ OMX – NASDAQ Basic Amex
LandUnited States of America
Postleitzahl35806
Telefon12563279630
Websitehttps://serinatherapeutics.com/
BörsenkürzelSER
IPO-datumNov 29, 2018
CEOLedger (Steven)
Führungskräfte von Serina Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
67.24K
--
Dr. Randall W. Moreadith, M.D., Ph.D.
Dr. Randall W. Moreadith, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Mr. Steven Ledger
Mr. Steven Ledger
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Richard Marshall, M.D., Ph.D.
Mr. Richard Marshall, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Balkrishan (Simba) Gill, Ph.D.
Dr. Balkrishan (Simba) Gill, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Gregory S. (Greg) Curhan
Mr. Gregory S. (Greg) Curhan
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
--
--
Dr. Jay R. Venkatesan, M.D.
Dr. Jay R. Venkatesan, M.D.
Independent Director
Independent Director
--
--
Dr. Stephen (Steve) Brannan, M.D.
Dr. Stephen (Steve) Brannan, M.D.
Independent Director
Independent Director
--
--
Dr. Srini Tenjarla, Ph.D.
Dr. Srini Tenjarla, Ph.D.
Senior Vice President - CMC and Formulation
Senior Vice President - CMC and Formulation
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
67.24K
--
Dr. Randall W. Moreadith, M.D., Ph.D.
Dr. Randall W. Moreadith, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Mr. Steven Ledger
Mr. Steven Ledger
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Richard Marshall, M.D., Ph.D.
Mr. Richard Marshall, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Balkrishan (Simba) Gill, Ph.D.
Dr. Balkrishan (Simba) Gill, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Gregory S. (Greg) Curhan
Mr. Gregory S. (Greg) Curhan
Chief Financial Officer
Chief Financial Officer
--
--
Umsatzaufteilung
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach RegionUSD
Name
Umsatz
Anteil
United States
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sat, Nov 15
Aktualisiert: Sat, Nov 15
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Juvenescence Ltd
30.64%
Puffinus L.P.
8.49%
McMillan (Helen w)
6.64%
The Vanguard Group, Inc.
1.69%
Ledger (Steven A)
0.90%
Andere
51.65%
Aktionäre
Aktionäre
Anteil
Juvenescence Ltd
30.64%
Puffinus L.P.
8.49%
McMillan (Helen w)
6.64%
The Vanguard Group, Inc.
1.69%
Ledger (Steven A)
0.90%
Andere
51.65%
Aktionärstypen
Aktionäre
Anteil
Corporation
39.12%
Individual Investor
8.18%
Investment Advisor
2.92%
Hedge Fund
0.78%
Investment Advisor/Hedge Fund
0.54%
Research Firm
0.02%
Andere
48.43%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
56
461.23K
4.33%
-32.35K
2025Q3
56
464.13K
4.40%
+21.47K
2025Q2
59
6.70M
67.24%
+256.13K
2025Q1
61
6.74M
67.68%
+273.42K
2024Q4
60
6.52M
69.43%
+1.01M
2024Q3
60
5.48M
62.28%
+460.95K
2024Q2
62
5.34M
60.76%
+463.56K
2024Q1
62
4.83M
57.65%
+2.79M
2023Q4
55
610.31K
56.56%
+2.00K
2023Q3
59
606.40K
56.20%
-1.31K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Juvenescence Ltd
3.27M
30.64%
--
--
Sep 17, 2025
Puffinus L.P.
904.88K
8.49%
--
--
Sep 17, 2025
McMillan (Helen w)
708.61K
6.64%
-133.79K
-15.88%
Sep 17, 2025
The Vanguard Group, Inc.
180.01K
1.69%
+29.39K
+19.51%
Sep 30, 2025
Ledger (Steven A)
95.73K
0.9%
-227.93K
-70.42%
Sep 17, 2025
Broadwood Capital, Inc.
83.19K
0.78%
-2.02K
-2.38%
Sep 30, 2025
Waverly Advisors, LLC
67.49K
0.63%
--
--
Sep 30, 2025
Bailey (Gregory Hugh)
67.24K
0.63%
--
--
Sep 17, 2025
Geode Capital Management, L.L.C.
29.61K
0.28%
+724.00
+2.51%
Sep 30, 2025
Linscomb & Williams, Inc.
18.80K
0.18%
+18.80K
--
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
Anteil0%
iShares Core S&P Total U.S. Stock Market ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
Datum
Ex-Dividendentag
Art
Verhältnis
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
